P147 Solriamfetol Titration & AdministRaTion (START): Characteristics of patients with obstructive sleep apnoea (OSA) and prescriber rationale for starting treatment with solriamfetol

INTRODUCTION: Solriamfetol (Sunosi) is a dopamine/norepinephrine reuptake inhibitor approved (EU/US) to treat excessive daytime sleepiness (EDS) in adults with OSA (37.5–150 mg/day) or narcolepsy (75–150 mg/day). This study examined characteristics of patients with OSA initiating solriamfetol and pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, H, Hyman, D, Parks, G, Chen, A, Foley, C, Ito, D, Thorpy, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Poster Presentations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10109363/
http://dx.doi.org/10.1093/sleepadvances/zpab014.188

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10109363/
http://dx.doi.org/10.1093/sleepadvances/zpab014.188

Ejemplares similares